Getulio

@doctorinigo @lowcarbGP The study has critical flaws: retrospective design, no BMI data during follow-up, and exclusion of patients with psychiatric history. Prospective studies are essential for valid conclusions

This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) like Liraglutide and Semaglutide on psychiatric conditions in obese patients. Using post-marketing data from 2015 to 2023 and propensity score matching, it compares patients prescribed GLP-1 RAs with those not taking these medications. Results show a 98% increased risk of psychiatric disorders, with higher risks for: -Major depression (195%) -Anxiety (108%) -Suicidal behavior (106%) The findings highlight the need for careful patient assessment before prescribing GLP-1 RAs. Further clinical trials are needed to understand the mental health implications of GLP-1 RA use. nature.com/articles/s4159…

Obesidade não é uma escolha! Buscar ajuda para emagrecer é!

@Bancointer o/

O Interpig embarcou na nave do Mandaloriano nesse #StarWarsDay e precisa da sua ajuda pra encontrar um novo lar. Quem aí aceita abrigar essa fofura? #MayThe4thBeWithYou